Academic Journal
Factors Affecting Acceptance of Participating in Clinical Trials of New Drugs: A National Cross-Sectional Study.
| Τίτλος: | Factors Affecting Acceptance of Participating in Clinical Trials of New Drugs: A National Cross-Sectional Study. |
|---|---|
| Συγγραφείς: | Dong S; Department of Pharmacy, Peking University Third Hospital, Beijing, China.; Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China., Liu M; Department of Pharmacy, Peking University Third Hospital, Beijing, China., Zhang Y; Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China., Zhang J; Graduate School, Harbin Medical University, Harbin, China., Han Q; School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China., Chen X; Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China., Wu Y; Department of Nursing, the Fourth Affiliated Hospital of School of Medicine and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China., Ming WK; Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China. |
| Πηγή: | Journal of evidence-based medicine [J Evid Based Med] 2026 Sep; Vol. 19 (3), pp. e70176. Date of Electronic Publication: 2026 Aug 26. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101497477 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1756-5391 (Electronic) Linking ISSN: 17565391 NLM ISO Abbreviation: J Evid Based Med Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Oxford : Wiley-Blackwell |
| Ιατρικοί όροι (MeSH): | Clinical Trials as Topic*/psychology , Patient Acceptance of Health Care*/statistics & numerical data , Patient Acceptance of Health Care*/psychology, Humans ; Cross-Sectional Studies ; Female ; China ; Middle Aged ; Male ; Adult ; Surveys and Questionnaires ; Aged ; Young Adult |
| Περίληψη: | Objective: Clinical trials are regarded as an essential method for developing new treatments and giving patients access to potentially effective medications that are still being studied. This study aimed to evaluate acceptance of participating in clinical trials of new drugs and to further explore the associated factors. Methods: A population-based cross-sectional study was conducted in China from June 20 to August 31, 2022. We collected demographic data and used visual analog scale scores to assess the public's willingness to accept clinical trials of new drugs (range 0-100). Linear regression analysis was adopted to evaluate the factors related to attitudes toward clinical trials of new drugs. Results: This survey contained 19,710 valid questionnaires to investigate acceptance of participating in clinical trials of new drugs. Participants showed low willingness to accept clinical trials of new drugs, with a mean score of 44.69 out of 100. The results showed that rural residence (β = 3.00), western China (β = 3.15), being married (β = 2.93), older age (31-59 years [β = 3.84], ≥60 years [β = 7.71]), having cancer or rare diseases (β = 5.15), higher monthly household income (>6000 yuan [β = 1.76]), medical-related occupations (β = 8.01), anxiety status (moderate anxiety [β = 1.83]), moderate to severe anxiety [β = 2.66]), perceived stress (β = 0.51), health literacy (β = 0.21), self-efficacy (β = 0.34), and media use (β = 0.42) were associated with higher acceptance of participating in clinical trials of new drugs. However, central China (β = -1.65), female sex (β = -2.29), chronic diseases (β = -2.45), and medical insurance (β = -3.78) were associated with lower acceptance of participating in clinical trials of new drugs. Subgroup analysis demonstrated consistent trends across age and chronic disease subgroups. Conclusions: This reveales low public willingness to accept clinical trials of new drugs. The willingness is affected by marital status, occupation, area of residence, income, health insurance, physical and mental health status, media use, and health literacy. (© 2026 The Author(s). Journal of Evidence‐Based Medicine published by Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.) |
| References: | Arch Intern Med. 2006 May 22;166(10):1092-7. (PMID: 16717171) Health Lit Res Pract. 2019 Apr 10;3(2):e91-e102. (PMID: 31294310) J Affect Disord. 2021 Jan 15;279:473-483. (PMID: 33126078) J Health Commun. 2017 May;22(5):373-385. (PMID: 28339327) Clin Trials. 2015 Jun;12(3):215-23. (PMID: 25673636) Qual Life Res. 2011 Dec;20(10):1727-36. (PMID: 21479777) J Clin Oncol. 2013 Feb 10;31(5):536-42. (PMID: 23295802) J Infect Public Health. 2019 Sep - Oct;12(5):673-680. (PMID: 31006634) BMJ Open Qual. 2022 Oct;11(4):. (PMID: 36316063) PLoS One. 2014 Oct 16;9(10):e109652. (PMID: 25329072) Contemp Clin Trials. 2021 Apr;103:106315. (PMID: 33626412) Risk Manag Healthc Policy. 2025 Apr 01;18:1121-1131. (PMID: 40190729) BMC Psychiatry. 2020 Mar 20;20(1):130. (PMID: 32197589) Int J Environ Res Public Health. 2023 Feb 11;20(4):. (PMID: 36833899) JAMA Netw Open. 2018 Oct 5;1(6):e182969. (PMID: 30646218) South Med J. 2017 Apr;110(4):270-277. (PMID: 28376524) Patient Educ Couns. 2016 Jul;99(7):1079-1086. (PMID: 26899632) BMJ Open. 2019 Oct 22;9(10):e031305. (PMID: 31641002) BMC Palliat Care. 2023 Jul 10;22(1):91. (PMID: 37424005) Cyberpsychol Behav Soc Netw. 2011 Oct;14(10):613-8. (PMID: 21548797) Behav Neurol. 2023 Nov 24;2023:5617575. (PMID: 38046475) JAMA Netw Open. 2021 Sep 1;4(9):e2127792. (PMID: 34586365) Value Health. 2017 Apr;20(4):662-669. (PMID: 28408009) Front Public Health. 2024 Apr 11;12:1276536. (PMID: 38665243) J Gen Intern Med. 2006 Aug;21(8):867-73. (PMID: 16881949) J Clin Oncol. 2003 Mar 1;21(5):830-5. (PMID: 12610181) Psychooncology. 2013 Mar;22(3):481-9. (PMID: 22331643) JAMA. 1999 Feb 10;281(6):545-51. (PMID: 10022111) J Health Commun. 2015;20(7):816-26. (PMID: 26042496) BMC Public Health. 2015 Jan 17;15:10. (PMID: 25595373) PLoS One. 2016 Feb 05;11(2):e0143893. (PMID: 26848750) Sci Rep. 2023 Nov 9;13(1):19550. (PMID: 37945746) J Am Med Dir Assoc. 2023 Feb;24(2):206-212.e5. (PMID: 36370750) J Clin Oncol. 2005 Dec 20;23(36):9282-9. (PMID: 16361626) J Natl Cancer Inst. 2021 Mar 1;113(3):244-257. (PMID: 33022716) Stress Health. 2016 Apr;32(2):173-6. (PMID: 24995556) Commun Med (Lond). 2022 Jul 25;2:94. (PMID: 35903184) Biol Psychiatry. 2012 Jul 15;72(2):113-8. (PMID: 22325982) Clin Med (Lond). 2022 Sep;22(5):416-422. (PMID: 36507814) Front Public Health. 2022 Mar 03;10:855457. (PMID: 35309228) MedEdPublish (2016). 2017 May 11;6:83. (PMID: 38406464) Eur J Med Chem. 2023 Aug 5;256:115476. (PMID: 37207534) Front Public Health. 2024 Mar 14;12:1355392. (PMID: 38550320) J Gen Intern Med. 2001 Sep;16(9):606-13. (PMID: 11556941) J Affect Disord. 2021 Mar 1;282:98-103. (PMID: 33401129) BMC Public Health. 2021 Jun 10;21(1):1106. (PMID: 34112143) |
| Grant Information: | 72304009 National Natural Science Foundation of China; 7020093 SIRG-CityU Strategic Interdisciplinary Research |
| Contributed Indexing: | Keywords: clinical trial; cross‐sectional study; new drug; public willingness |
| Entry Date(s): | Date Created: 20260826 Date Completed: 20260925 Latest Revision: 20260927 |
| Update Code: | 20260927 |
| PubMed Central ID: | PMC13613238 |
| DOI: | 10.1111/jebm.70176 |
| PMID: | 42644647 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1756-5391 |
|---|---|
| DOI: | 10.1111/jebm.70176 |